Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Pact Pharma Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 4 distinct examiners and 4 distinct art units, showing that the portfolio’s active prosecution is distributed across separate examination assignments.
REDDIG, PETER J is the busiest listed examiner, with 1 pending matter. Because no examiner or art unit carries the full active workload, counsel should manage responses matter by matter while maintaining consistent positions on related biotechnology and pharmaceutical concepts.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REDDIG, PETER J | 1 | 58.0% | +40.2% |
| CORDAS, EMILY ANN | 1 | 50.9% | +57.4% |
| LEE, YIE CHIA | 1 | 69.2% | +46.6% |
| HOLLAND, PAUL J | 1 | 57.3% | +64.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18049114 | METHODS OF DETERMINING GENE EDITING EFICIENCIES IN CELLS | HOLLAND, PAUL J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18332169 | METHODS OF TREATMENT USING A GENETICALLY MODIFIED AUTOLOGOUS T CELL IMMUNOTHERAPY | REDDIG, PETER J | 97d overdue |
| 18306927 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING NEXT GENERATION ENGINEERED T CELL THERAPY | LEE, YIE CHIA | 74d overdue |
| 18319743 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TGFßRII ENGINEERED T CELL THERAPY | CORDAS, EMILY ANN | — |
| 18049114 | METHODS OF DETERMINING GENE EDITING EFICIENCIES IN CELLS | HOLLAND, PAUL J | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1632 | 1 |
| 1642 | 1 |
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18332169 | METHODS OF TREATMENT USING A GENETICALLY MODIFIED AUTOLOGOUS T CELL IMMUNOTHERAPY | REDDIG, PETER J | 1646 | §102§103§112DP | Non-Final OA | 97d overdue | Pending | Jun 09, 2023 |
| 18319743 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TGFßRII ENGINEERED T CELL THERAPY | CORDAS, EMILY ANN | 1632 | §103 | Non-Final OA | — | Pending | May 18, 2023 |
| 18306927 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING NEXT GENERATION ENGINEERED T CELL THERAPY | LEE, YIE CHIA | 1642 | §103 | Final Rejection | 74d overdue | Pending | Apr 25, 2023 |
| 18049114 | METHODS OF DETERMINING GENE EDITING EFICIENCIES IN CELLS | HOLLAND, PAUL J | 1656 | §103§112 | Non-Final OA | — | Pending | Oct 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPact Pharma Inc. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Peter J Reddig has the most, with 1 of Pact Pharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
